Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis

This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.

Inclusion Criteria:

• The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;
• The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;
• The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis

Exclusion Criteria:

• Those who may be allergic to VC005, similar drugs or their excipients.
• Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.
• Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.